Related Experiment Video
Updated: Dec 19, 2025
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.9K
Case report: Neoadjuvant systemic therapy for melanoma
Natiya Gabuniya1, Ankur Khajuria1,2, Jenny L C Geh1
1Guy's and St Thomas NHS Foundation Trust, United Kingdom.
Annals of Medicine and Surgery (2012)
|June 4, 2020
Summary
A case study shows neoadjuvant targeted chemotherapy successfully shrank advanced metastatic melanoma, enabling safe surgical removal. This approach offers a viable option for challenging melanoma cases.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Metastatic melanoma presents significant treatment challenges, particularly when lesions are large or in difficult locations.
- Surgical resection is a primary treatment, but large metastatic lesions pose risks of surgical complications.
- Systemic therapies are crucial for managing advanced melanoma, but their role as neoadjuvant treatment requires further investigation.
Observation:
- A 45-year-old male with a history of thin melanoma resection presented with a rapidly enlarging metastatic lesion.
- The lesion's size and location presented a surgical challenge, necessitating alternative treatment strategies.
- Neoadjuvant targeted chemotherapy was administered to reduce tumor burden prior to definitive surgery.
Findings:
- The neoadjuvant targeted chemotherapy resulted in a significant reduction in the metastatic melanoma lesion size.
- This size reduction facilitated a subsequent safe surgical resection.
- Histopathology confirmed no residual disease after the combined neoadjuvant and surgical treatment approach.
Implications:
- Neoadjuvant targeted chemotherapy is an effective strategy for downstaging advanced metastatic melanoma.
- This approach can mitigate surgical risks associated with large or strategically located lesions.
- Successful neoadjuvant therapy followed by resection offers a promising treatment paradigm for advanced melanoma, potentially improving patient outcomes.
